Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics Q3 net loss narrows to $21.9 million; cash falls to $31.1 million

Positive Impact 3 of 5 earnings

Aligos Therapeutics reported third quarter 2026 results on November 6, 2026, with a net loss of $21.9 million, down from $31.5 million a year earlier, as revenue rose and research and development spending fell to $18.9 million. Cash, cash equivalents and investments of $31.1 million are expected to fund planned operations only into the first quarter of 2027.

Key points

  • Net loss for the three months ended September 30, 2026 was $21.9 million, or $(2.09) per share, versus $31.5 million, or $(3.04) per share, a year earlier.
  • Revenue from customers was $2.8 million, up from $0.7 million, and licensing revenue was $39 thousand, compared with none in the prior-year quarter.
  • Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, down from $77.8 million at December 31, 2025.
  • Topline data from the Phase 2 B-SUPREME study of pevifoscorvir sodium are expected in late Q3 2027.

The filing

CompanyAligos Therapeutics, Inc. (ALGS)
Form8-K, current report
Filed with the SECNov 6, 2026, 8:00 AM ET
Accession number0001171843-26-007214

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.